Similar articles for PMID: 31626859

Year	Number of Results
1988	1
1989	1
1990	1
1992	1
1996	3
1997	3
1998	5
1999	1
2000	6
2001	1
2002	5
2003	1
2004	3
2005	2
2006	5
2007	2
2008	2
2009	5
2010	4
2011	6
2012	4
2013	4
2014	5
2015	8
2016	7
2017	8
2018	3
2019	8
2020	7
2021	8
2022	10
2023	9
2024	0

1

In vivo characterization of enTRinsic™ drug delivery technology capsule after intake in fed state: A cross-validation approach using salivary tracer technique in comparison to MRI.

Sager M, Grimm M, Aude P, Schick P, Merdivan S, Hasan M, Kromrey ML, Sivert A, Benameur H, Koziolek M, Tzvetkov MV, Weitschies W. Sager M, et al. J Control Release. 2019 Nov 10;313:24-32. doi: 10.1016/j.jconrel.2019.10.023. Epub 2019 Oct 15. J Control Release. 2019. PMID: 31626859 Clinical Trial.

2

Combined Application of MRI and the Salivary Tracer Technique to Determine the in Vivo Disintegration Time of Immediate Release Formulation Administered to Healthy, Fasted Subjects.

Sager M, Grimm M, Jedamzik P, Merdivan S, Kromrey ML, Hasan M, Koziolek M, Tzvetkov MV, Weitschies W. Sager M, et al. Mol Pharm. 2019 Apr 1;16(4):1782-1786. doi: 10.1021/acs.molpharmaceut.8b01320. Epub 2019 Mar 8. Mol Pharm. 2019. PMID: 30821987

3

Low dose caffeine as a salivary tracer for the determination of gastric water emptying in fed and fasted state: A MRI validation study.

Sager M, Jedamzik P, Merdivan S, Grimm M, Schneider F, Kromrey ML, Hasan M, Oswald S, Kühn J, Koziolek M, Weitschies W. Sager M, et al. Eur J Pharm Biopharm. 2018 Jun;127:443-452. doi: 10.1016/j.ejpb.2018.03.011. Epub 2018 Mar 27. Eur J Pharm Biopharm. 2018. PMID: 29602018

4

Characterization of the gastrointestinal transit and disintegration behavior of floating and sinking acid-resistant capsules using a novel MRI labeling technique.

Grimm M, Ball K, Scholz E, Schneider F, Sivert A, Benameur H, Kromrey ML, Kühn JP, Weitschies W. Grimm M, et al. Eur J Pharm Sci. 2019 Mar 1;129:163-172. doi: 10.1016/j.ejps.2019.01.012. Epub 2019 Jan 10. Eur J Pharm Sci. 2019. PMID: 30639530

5

Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.

Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, Yoshikawa Y, Takada K. Muraoka M, et al. J Control Release. 1998 Mar 2;52(1-2):119-29. doi: 10.1016/s0168-3659(97)00201-0. J Control Release. 1998. PMID: 9685942

6

The Effect of Capsule-in-Capsule Combinations on In Vivo Disintegration in Human Volunteers: A Combined Imaging and Salivary Tracer Study.

Rump A, Weiss FN, Schulz L, Kromrey ML, Scheuch E, Tzvetkov MV, White T, Durkee S, Judge KW, Jannin V, Bellamine A, Weitschies W, Grimm M. Rump A, et al. Pharmaceutics. 2021 Nov 25;13(12):2002. doi: 10.3390/pharmaceutics13122002. Pharmaceutics. 2021. PMID: 34959284 Free PMC article.

7

Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects.

Hu Z, Mawatari S, Shibata N, Takada K, Yoshikawa H, Arakawa A, Yosida Y. Hu Z, et al. Pharm Res. 2000 Feb;17(2):160-7. doi: 10.1023/a:1007561129221. Pharm Res. 2000. PMID: 10751030 Clinical Trial.

8

In Vivo Evaluation of a Gastro-Resistant HPMC-Based "Next Generation Enteric" Capsule.

Rump A, Kromrey ML, Scheuch E, Jannin V, Rehenbrock L, Tzvetkov MV, Weitschies W, Grimm M. Rump A, et al. Pharmaceutics. 2022 Sep 21;14(10):1999. doi: 10.3390/pharmaceutics14101999. Pharmaceutics. 2022. PMID: 36297435 Free PMC article.

9

Characterization of the behavior of alginate-based microcapsules in vitro and in vivo.

Anschütz M, Garbacz G, Kosch O, Donath F, Wiedmann J, Hoeckh W, Trahms L, Schug B, Weitschies W, Blume H. Anschütz M, et al. Int J Clin Pharmacol Ther. 2009 Sep;47(9):556-63. doi: 10.5414/cpp47556. Int J Clin Pharmacol Ther. 2009. PMID: 19761714

10

Comparing the gastric emptying of 240 mL and 20 mL water by MRI and caffeine salivary tracer technique.

Grimm M, Aude P, Feldmüller M, Keßler R, Scheuch E, Tzvetkov MV, Koziolek M, Weitschies W. Grimm M, et al. Eur J Pharm Biopharm. 2023 Mar;184:150-158. doi: 10.1016/j.ejpb.2023.01.021. Epub 2023 Feb 1. Eur J Pharm Biopharm. 2023. PMID: 36736963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

124 results

Results by year